Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia

Ultrasound in Obstetrics and Gynecology

Volumn 47, Issue 4, 2016, Pages 478-483

  Tsiakkas, A ^a   Mendez, O ^a   Wright, A ^b   Wright, D ^b   Nicolaides, K H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Bayes' theorem; impaired placentation; pre eclampsia; pyramid of pregnancy care; screening; sFlt 1

Indexed keywords

BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

BAYES THEOREM; BLOOD; FEMALE; GESTATIONAL AGE; HUMAN; PRE-ECLAMPSIA; PREDICTIVE VALUE; PREGNANCY; PREMATURE BIRTH; PRENATAL DIAGNOSIS; PROCEDURES; PROSPECTIVE STUDY;

BAYES THEOREM; BIOMARKERS; FEMALE; GESTATIONAL AGE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTERS; PREMATURE BIRTH; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84960424959     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.15817     Document Type: Article

References (25)

1. World Health Organization. Make every mother and child count. World Health Report, 2005. Geneva, Switzerland: World Health Organization; 2005.
2. Confidential Enquiry into Maternal and Child Health (CEMACH) Perinatal Mortality 2006: England, Wales and Northern Ireland. London, United Kingdom: CEMACH; 2008.
3. Duley L., The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137.
4. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y,. Prevention of pre-eclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414.
5. Roberge S, Nicolaides K, Demers S, Villa P, Bujold E,. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013; 41: 491-499.
6. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG; HYPITAT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979-988.
7. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH,. Competing risks model in screening for pre-eclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015; 213: 62.e1-10.
8. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH,. A competing risks model in early screening for pre-eclampsia. Fetal Diagn Ther 2012; 32: 171-178.
9. O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH,. Competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Am J Obstet Gynecol 2015; 213: 62.e1-10.
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA,. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med 2004; 350: 672-683.
11. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS,. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of pre-eclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-207.
12. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H,. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58.e1-8.
13. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA,. Angiogenic factors and the risk of adverse outcomes in women with suspected pre-eclampsia. Circulation 2012; 125: 911-919.
14. Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH. Competing risks model in screening for pre-eclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther 2014; 35: 240-248.
15. Maynard SE, Min JY, Merchan J, Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA,. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre-eclampsia. J Clin Invest 2003; 111: 649-658.
16. Robinson HP, Fleming JE,. A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 1975; 82: 702-710.
17. Snijders RJ, Nicolaides KH,. Fetal biometry at 14-40 weeks' gestation. Ultrasound Obstet Gynecol 1994; 4: 34-48.
18. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM,. The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the international society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV.
19. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH,. Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 584-590.
20. Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH,. Competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation. Ultrasound Obstet Gynecol 2015. DOI: 10.1002/uog.15812.
21. R Development Core Team. R. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2011; ISBN 3-900051-07-0; http://www.R-project.org /.
22. Therneau T. A Package for survival analysis in S. R package version 2.37-7, 2014; https://cran.r-project.org/web/packages/survival/index.html
23. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Peguero A, Dominguez C, Gratacós E. Added value of angiogenic factors for the prediction of early and late pre-eclampsia in the first trimester of pregnancy. Fetal Diagn Ther 2014; 35: 258-266.
24. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, Llurba E, Gratacós E,. First trimester screening for early and late pre-eclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn 2015; 35: 183-191.
25. Nicolaides KH,. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.